Nuvalent, Inc. (NUVL) Stock Price & Analysis
Nuvalent, Inc. (NUVL) rose 0.00% to USD 123.96 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
NUVL last closed at USD 0; the session ranged USD 123.95–123.99 on volume of 3,085,847 shares. Market capitalization is $9.81B, with a 52-week range of USD 71.13–123.99 (NGM). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 123.96 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 123.96 |
| Day Range | USD 123.95 – 123.99 |
| 52-Week Range | USD 71.13 – 123.99 |
| Volume | 3,085,847 shares |
| Market Cap | $9.81B |
| Exchange | NGM |
Technical Analysis (NUVL)
Nexqual's technical model rates NUVL "BUY" based on 5 bullish and 2 bearish signals across 122 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 85.04 (overbought) |
| vs SMA50 | Above (USD 113.93) |
| MACD | 2.51 (positive) |
Analyst Ratings (NUVL)
Wall Street analysts rate NUVL "Hold" based on 9 analysts, with a mean price target of USD 124 (range USD 124–124), per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 124 |
| High Target | USD 124 |
| Low Target | USD 124 |
| Buy / Hold / Sell | 0 / 9 / 0 |
Earnings (NUVL)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -1.38 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.39 vs est -1.31 ▼ miss |
| 2025-12-31 | USD -1.58 vs est -1.44 ▼ miss |
| 2025-09-30 | USD -1.7 vs est -1.32 ▼ miss |
| 2025-06-30 | USD -1.39 vs est -1.15 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (NUVL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -41.19% |
| Current Ratio | 16.14 |
| Total Cash | $1.29B |
| Total Debt | $0 |
| Free Cash Flow | $-180.43M |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (NUVL)
Nexqual rates Nuvalent, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $1.29B cash, no debt |
| Cash Flow | Weak — Operating cash flow -$313M |
| Efficiency | Critical — ROE -41%, ROA -22.5% |
Ownership (NUVL)
| Insider Ownership | +2.78% |
|---|---|
| Institutional Ownership | +113.30% |
| Shares Outstanding | 73.69M |
| Float | 49.11M |
| Short % of Float | +6.17% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (NUVL)
Nuvalent, Inc. is led by Ruth Adams, Senior Vice President of Clinical Operations, per Nexqual as of July 25, 2026 at 03:44 UTC.
| Senior Vice President of Clinical Operations | Ruth Adams |
|---|
Major Backers & Investors (NUVL)
Notable institutional backers of Nuvalent, Inc. include Deerfield Management Company, L.P, FMR, LLC, Paradigm Biocapital Advisors LP, according to Nexqual as of July 25, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 23.45% |
| FMR, LLC | 12.61% |
| Paradigm Biocapital Advisors LP | 7.24% |
| JPMorgan | 5.03% |
| RA Capital Management, L.P. | 3.44% |
| Wellington Management | 3.36% |
| Price (T.Rowe) Associates Inc | 2.8% |
| Fidelity | 2.51% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.08% |
| BlackRock | 8.19% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
From Nuvalent, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of oncology.
- While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge provide us with competitive advantages, we face competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.
- Any owned or in-licensed patent rights we may obtain may not enable us to prevent others from replicating, manufacturing, using, or administering our product candidates for any indication.
- We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development and commercialization, if approved, of our product candidates.
Partnerships
- Revenue Sharing Agreement with our scientific founder We are party to an Amended and Restated Revenue Sharing Agreement with our scientific founder, Matthew Shair, Ph.D., pursuant to which we were obligated to pay Dr.
- We prioritize therapeutic targets where patient needs and limitations of existing therapies can be identified and characterized in partnership with physician-scientists.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
| IDYA | IDEAYA Biosciences, Inc. | USD 35.4 | ▲ 1.14% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.